South Korean medical aesthetics and pharmaceutical companies are advancing their global supply-chain presence. Huons Meditech presented clinical strategies for its DermaShine Duo RF and Lincurve Pro HIFU devices at the 2026 Korean Society of Clinical Aesthetic Medicine conference, signaling continued innovation in energy-based aesthetic devices. Separately, KM Pharmaceutical signed an MOU with a US partner to expand distribution of its oral care and lifestyle beauty OEM/ODM products, including military and institutional channels, targeting the North American market.
Huons Meditech at KSCAM 2026
Huons Meditech, a medical device subsidiary of Huons Global, participated in the 2026 Korean Society of Clinical Aesthetic Medicine (KSCAM) conference held on May 31 at the Grand InterContinental Seoul Parnas Hotel. The event gathered domestic aesthetic medicine professionals to share the latest clinical trends and procedural know-how in skin aesthetics and energy-based treatments.
Clinical Strategy for DermaShine Duo RF and Lincurve Pro
During the academic program, Dr. Kim Hae-sol of Samsung Nobel Clinic presented on "3D Multi-layer Lifting and Dermal Remodeling Optimization Strategy through Fusion of HIFU and Needle RF." The lecture covered energy delivery differences based on facial anatomy and curvature, along with skin-layer-specific approaches and energy settings. Attendees showed strong interest in Huons Meditech's DermaShine Duo RF and the Lincurve Pro, a curved-cartridge HIFU device.
Company Strategy and Buyer Implications
Huons Meditech CEO Ha Chang-woo stated, "Lincurve Pro was developed considering facial anatomical curves and procedural convenience, meeting diverse clinician needs." He added that the company plans to accelerate product awareness and clinical case dissemination through a symposium in June. For overseas buyers, this signals Huons Meditech's commitment to expanding academic marketing and hands-on training programs, potentially offering advanced RF and HIFU solutions for clinic setups.
KM Pharmaceutical MOU for North America
KM Pharmaceutical (KOSDAQ: 225430), an oral care and lifestyle beauty OEM/ODM specialist, signed an MOU with a US partner during CEO Baek Seung-won's business trip to the US. The partner specializes in government and institutional procurement channels, providing access to B2B and institutional distribution networks that are difficult for general consumer goods companies to penetrate alone.
Four-Pronged Cooperation Framework
The MOU outlines four collaboration areas: (1) expanding distribution of KM's own brands ZEROCIPE (hair care) and FOAMGLE (oral care) in North America; (2) OEM/ODM production in Korea for the partner's new US brands in foam oral care, skincare, and health functional foods; (3) joint pursuit of OEM supply opportunities for major US retailers' private-label products; and (4) exploring entry into US military channels for foam oral care products.
Sourcing Context for Buyers
KM Pharmaceutical leverages its proprietary foam oral care technology and mass production experience to serve as a stable manufacturing partner. CEO Baek noted, "Expanding beyond retail into high-barrier channels like military and B2B is true market capture." The company emphasized that while the MOU is non-binding, it marks a milestone in its mid- to long-term strategy to increase North American revenue share. For overseas distributors and clinic buyers, this partnership may open new OEM/ODM sourcing opportunities for oral care and beauty products tailored to US institutional and retail markets.
Source: Read the original report | Published: June 01, 2026